Laurus Labs inks pact with MPP to produce molnupiravir
PTI, Jan 21, 2022, 11:46 AM IST
Image Source: Wikimedia
New Delhi: Drug firm Laurus Labs on Friday said it has inked a pact with Geneva-based MPP (Medicine Patient Pool) for manufacturing the oral COVID-19 antiviral medication molnupiravir.
”We are happy to sign an agreement to manufacture the oral COVID-19 anti-viral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission,” Laurus Labs Founder and CEO Satyanarayana Chava said in a regulatory filing.
Molnupiravir is an orally administered ribonucleoside analog that inhibits the replication of SARS CoV2, and clinical studies have shown this drug to be active against the most common COVID-19 variants.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Markets fall in early trade amid unabated foreign fund outflows
New software for fast-tracking project approvals: Karnataka Minister Patil
In-flight passengers can access WiFi services only when allowed, say new rules
SEBI mulls separation of non-regulated activities; ‘cross-default’ definition for debenture trustees
Sensex plunges 942 points to settle at nearly 3-month low; RIL, HDFC Bank biggest drag
MUST WATCH
Latest Additions
Like UP, bring BJP to power in Jharkhand to ‘bulldoze’ mafia: Yogi at Koderma poll rally
Govt asks Wikipedia why it should not be treated as publisher instead of intermediary
MUDA Case: K’taka HC adjourns hearing to November 26
SC upholds validity of UP madrassa law, says it does not violate principle of secularism
Union Minister H D Kumaraswamy booked for threatening police officer
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.